Newly diagnosed acute myeloid leukemia patients aged equal or more than 60 years old research hub

A phase I-II, multicentre, open label clinical trial to assess the safety and tolerability of the combination of low-dose cytarabine or azacitidine, plus Venetoclax and Quizartinib in newly diagnosed acute myeloid leukemia patients aged equal or more than 60 years old ineligible for standard induction chemotherapy

This study looks at new treatments for older patients with acute myeloid leukaemia (AML) who can't have standard chemotherapy. It combines three medicines to see if they are safe and effective, aiming to improve treatment outcomes.